Hi All,
Has everyone seen and read the following?
Is this not what the market wants to read in the upcoming K9 trials?
IMO, the second paragraph two says it all...and IMO, is a prelude the the imminent announcement.
MPL Clinical Trials in Dogs Diagnosed with CancerIn a Phase I trial conducted in dogs diagnosed with solid tumours, MPL was shown to be well tolerated and reported as beneficial to Quality of Life (QOL) in canines with cancer doses up to 25 mg/kg bw daily either as monotherapy or at 5 mg/kg bw in combination with carboplatin. Further, MPL dosed at 5 mg/kg bw daily in canines with “standard of care” treatment-refractory cancer effectively and significantly reduces blood levels of the cancer-specific marker p-Rbps6k.
In a Phase 2 pilot programme, dogs diagnosed with lymphoma were treated with MPL as front-line therapy with doses up to 25mg/kg/day for two weeks before transitioning to standard therapy. Results showed that 100% of dogs diagnosed with B-cell lymphoma developed stable disease and showed evidence of tumour regression with minimal side-effects following MPL treatment. Lymphoma in dogs is very aggressive and, without treatment, the tumours are often fatal within weeks.
(Taken from PharmAust's website under pipelines and trials.)
Looking forward to the canine results........
AS Always
Best
Mickey Mouse
- Forums
- ASX - By Stock
- PAA
- MPL Clinical Trials in Dogs Diagnosed with Cancer - RESULTS from B-cell lymphoma trials.
MPL Clinical Trials in Dogs Diagnosed with Cancer - RESULTS from B-cell lymphoma trials.
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.5¢ |
Change
0.035(10.3%) |
Mkt cap ! $146.4M |
Open | High | Low | Value | Volume |
34.5¢ | 38.0¢ | 34.5¢ | $542.7K | 1.474M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 14511 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 18443 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 14511 | 0.370 |
1 | 22900 | 0.365 |
2 | 39000 | 0.360 |
4 | 40571 | 0.350 |
5 | 78460 | 0.340 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 18443 | 1 |
0.380 | 173372 | 6 |
0.385 | 5000 | 1 |
0.390 | 35000 | 2 |
0.395 | 97051 | 5 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
37.0¢ |
  |
Change
0.035 ( 8.82 %) |
|||
Open | High | Low | Volume | ||
34.5¢ | 38.0¢ | 34.5¢ | 757697 | ||
Last updated 15.59pm 28/03/2024 ? |
Featured News
PAA (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online